Hypoxic-ischemic brain injury (HIBI) remains one of the most critical challenges in neonatal medicine, particularly among very and extremely preterm infants. These infants face heightened risks of adverse neurodevelopmental outcomes due to insufficient oxygen and blood flow to the developing brain during the perinatal period. Despite advances in neonatal care, bedside tools for real-time and accurate quantification of early cerebral perfusion—a vital indicator of brain health—are scant. Addressing this gap, a groundbreaking study led by Kajikawa and colleagues, recently published in Pediatric Research, explores the intriguing interplay between soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) and cerebral blood volume (CBV) in these vulnerable neonates, highlighting potential clinical biomarkers and novel mechanistic insights into early brain injury.
sLOX-1, a soluble form of the membrane-bound receptor LOX-1, is widely recognized for its role in vascular inflammation and oxidative stress, primarily studied in adult cardiovascular disease. Its involvement in neonatal cerebral perfusion and injury, however, has been significantly understudied until now. Kajikawa et al. investigated sLOX-1 concentrations in the early neonatal period and correlated these levels with measures of cerebral blood volume assessed via advanced neuroimaging techniques. Their findings illuminate a potential early biomarker for compromised cerebral hemodynamics, which could transform clinical monitoring and intervention strategies in neonatal intensive care units (NICUs).
The study cohort comprised very and extremely preterm infants—defined here as those born before 32 weeks of gestation—a demographic notoriously susceptible to hypoxic-ischemic insults. Using a combination of cutting-edge cerebral perfusion imaging and precise immunoassays of sLOX-1 levels from blood samples, the researchers delineated a complex relationship that positions sLOX-1 as both a marker and possibly a mediator of neurovascular health in the fragile neonatal brain. Cerebral blood volume, a direct indicator of cerebral perfusion, was found to inversely correlate with sLOX-1 levels, suggesting that higher systemic inflammation and oxidative stress may drive reductions in cerebral perfusion.
This inverse correlation holds profound implications because cerebral hypoperfusion in preterm infants is a known precursor to white matter injury, intraventricular hemorrhage, and long-term neurodevelopmental deficits. Monitoring sLOX-1 early after birth could thus offer a minimally invasive and rapid method to identify patients at highest risk for these complications. Furthermore, the data suggests that therapeutic targeting of LOX-1 pathways might mitigate hypoxic-ischemic injury cascades, opening new avenues for pharmacological intervention that have, until now, been unexplored in neonatal neurology.
Beyond cerebral perfusion, the study also approached the role of intrauterine inflammation, a pervasive factor in preterm labor and adverse neurological outcomes. Elevated maternal inflammatory cytokines and fetal inflammatory responses have long been associated with heightened risk of periventricular leukomalacia and other brain injuries. Kajikawa and colleagues observed that sLOX-1 levels were significantly elevated in infants exposed to intrauterine inflammatory conditions such as chorioamnionitis, suggesting that sLOX-1 not only reflects oxidative stress and vascular dysfunction but may also serve as a proxy for inflammatory insult severity.
This dual insight into inflammation and perfusion underscores the multifactorial nature of brain injury in preterm neonates and the need for integrated biomarkers. By bridging oxidative stress, vascular health, and inflammatory status, sLOX-1 could become a pivotal biomarker in predicting and potentially preventing HIBI. The translational potential is immense: neonatologists could use sLOX-1 measurements to stratify risk, tailor supportive therapies, and monitor treatment efficacy in the crucial early hours and days after birth.
Technically, the study utilized advanced imaging modalities capable of quantifying cerebral blood volume with remarkable precision, circumventing the limitations of traditional ultrasound and standard magnetic resonance techniques. These innovations allow clinicians to monitor dynamic cerebral hemodynamics in real time, correlating physiological changes directly with biochemical markers like sLOX-1. Such integrative approaches embody the future of personalized neonatal neurocritical care, where molecular data complements imaging findings for comprehensive patient assessment.
Moreover, the mechanistic pathways implied by the study resonate with well-established concepts in adult vascular biology, where LOX-1 mediates endothelial dysfunction, promotes pro-inflammatory cytokine release, and exacerbates oxidative damage. Translating this knowledge to neonatal contexts highlights parallels but also distinct developmental susceptibilities. The immature neonatal vasculature and blood-brain barrier may be especially vulnerable to LOX-1-mediated injury, rendering sLOX-1 not merely a bystander but an active participant in the neuropathological process.
The researchers also emphasize the potential for sLOX-1 to serve as a target for novel therapeutics designed to modulate its activity or expression. Given that no FDA-approved drugs specifically antagonize LOX-1 for neonatal use, this research paves the way for future drug development initiatives. Experimental agents that inhibit LOX-1 signaling could reduce oxidative stress and vascular inflammation, preserving cerebral perfusion and preventing long-term neurodevelopmental impairment.
Clinical translation of these findings will require expanded multicenter studies to validate sLOX-1 as a reliable biomarker across diverse neonatal populations and to refine imaging protocols for practical bedside application. Additionally, longitudinal follow-up studies correlating early sLOX-1 levels with developmental milestones and neurocognitive outcomes will solidify its clinical value. These endeavors will demand sophisticated collaborations between neonatologists, neurologists, radiologists, and molecular scientists, underlining the interdisciplinary nature essential for advancing neonatal brain health.
Overall, the study by Kajikawa et al. marks a significant leap forward in understanding and potentially managing hypoxic-ischemic brain injury in preterm infants. By establishing soluble LOX-1 as a novel marker intricately linked to cerebral perfusion and intrauterine inflammation, it signals a paradigm shift in neonatal neurocritical care—a move towards precision diagnostics and tailored therapeutics that could save countless fragile lives and improve lifelong outcomes for survivors of prematurity.
With preterm birth rates rising globally and the persistent burden of neurodevelopmental disabilities, innovations that marry molecular insights with clinical practice are urgently needed. This research embodies that future, offering hope that a quicker, more accurate understanding of brain perfusion alterations and inflammatory processes may soon be within clinicians’ grasp, changing the fate of vulnerable newborns worldwide.
Kajikawa and colleagues’ findings invite the scientific and medical community to reconsider current neonatal monitoring standards and invest in biomarker-driven approaches. This leap from observational assessment to molecular precision heralds a new era where early and proactive intervention against hypoxic-ischemic injury becomes the norm rather than the exception, drastically improving the prognosis for preterm infants globally.
The elucidation of sLOX-1’s role not only advances our knowledge of neonatal pathophysiology but also inspires future research directions, from exploring genetic predispositions influencing LOX-1 expression to developing rapid bedside assays for sLOX-1. The translational potential spanning from bench to bedside is remarkable, promising both immediate and long-term impacts on neonatal critical care.
As this research field evolves, it will be essential to integrate these findings into comprehensive clinical guidelines that balance the complex interplay of inflammatory mediators, perfusion metrics, and developmental considerations. The ultimate goal remains clear: to prevent irreversible brain injury, safeguard neurodevelopment, and ensure that every preterm infant has the best possible start in life.
—
Subject of Research: Neonatal hypoxic-ischemic brain injury, cerebral perfusion, and biomarkers in preterm infants
Article Title: Early soluble LOX-1, cerebral perfusion, and intrauterine inflammation in very and extremely preterm infants
Article References:
Kajikawa, D., Sato, Y., Okada, Y. et al. Early soluble LOX-1, cerebral perfusion, and intrauterine inflammation in very and extremely preterm infants. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04618-5
Image Credits: AI Generated
DOI: 20 November 2025
